Literature DB >> 26702065

Targetable genetic features of primary testicular and primary central nervous system lymphomas.

Bjoern Chapuy1, Margaretha G M Roemer2, Chip Stewart3, Yuxiang Tan4, Ryan P Abo5, Liye Zhang4, Andrew J Dunford3, David M Meredith6, Aaron R Thorner5, Ekaterina S Jordanova7, Gang Liu4, Friedrich Feuerhake8, Matthew D Ducar5, Gerald Illerhaus9, Daniel Gusenleitner4, Erica A Linden10, Heather H Sun6, Heather Homer1, Miyuki Aono1, Geraldine S Pinkus6, Azra H Ligon6, Keith L Ligon6, Judith A Ferry11, Gordon J Freeman1, Paul van Hummelen5, Todd R Golub12, Gad Getz13, Scott J Rodig6, Daphne de Jong14, Stefano Monti4, Margaret A Shipp1.   

Abstract

Primary central nervous system lymphomas (PCNSLs) and primary testicular lymphomas (PTLs) are extranodal large B-cell lymphomas (LBCLs) with inferior responses to current empiric treatment regimens. To identify targetable genetic features of PCNSL and PTL, we characterized their recurrent somatic mutations, chromosomal rearrangements, copy number alterations (CNAs), and associated driver genes, and compared these comprehensive genetic signatures to those of diffuse LBCL and primary mediastinal large B-cell lymphoma (PMBL). These studies identify unique combinations of genetic alterations in discrete LBCL subtypes and subtype-selective bases for targeted therapy. PCNSLs and PTLs frequently exhibit genomic instability, and near-uniform, often biallelic, CDKN2A loss with rare TP53 mutations. PCNSLs and PTLs also use multiple genetic mechanisms to target key genes and pathways and exhibit near-uniform oncogenic Toll-like receptor signaling as a result of MYD88 mutation and/or NFKBIZ amplification, frequent concurrent B-cell receptor pathway activation, and deregulation of BCL6. Of great interest, PCNSLs and PTLs also have frequent 9p24.1/PD-L1/PD-L2 CNAs and additional translocations of these loci, structural bases of immune evasion that are shared with PMBL.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26702065      PMCID: PMC4760091          DOI: 10.1182/blood-2015-10-673236

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  68 in total

Review 1.  Primary diffuse large B-cell lymphoma of the testis.

Authors:  Matthew J Horne; Adebowale J Adeniran
Journal:  Arch Pathol Lab Med       Date:  2011-10       Impact factor: 5.534

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

4.  Shaping oncogenic NF-κB activity in the nucleus.

Authors:  Daniel Krappmann
Journal:  Blood       Date:  2013-09-26       Impact factor: 22.113

5.  High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.

Authors:  W Kraan; M van Keimpema; H M Horlings; E J M Schilder-Tol; M E C M Oud; L A Noorduyn; P M Kluin; M J Kersten; M Spaargaren; S T Pals
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

6.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

7.  Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination.

Authors:  Hye-Young Park; Heounjeong Go; Ha Rim Song; Suhyeon Kim; Geun-Hyoung Ha; Yoon-Kyung Jeon; Ji-Eun Kim; Ho Lee; Hyeseong Cho; Ho Chul Kang; Hee-Young Chung; Chul-Woo Kim; Doo Hyun Chung; Chang-Woo Lee
Journal:  J Clin Invest       Date:  2014-10-08       Impact factor: 14.808

8.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Authors:  Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

9.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

Authors:  Pilar Caro; Amar U Kishan; Erik Norberg; Illana A Stanley; Bjoern Chapuy; Scott B Ficarro; Klaudia Polak; Daniel Tondera; John Gounarides; Hong Yin; Feng Zhou; Michael R Green; Linfeng Chen; Stefano Monti; Jarrod A Marto; Margaret A Shipp; Nika N Danial
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

10.  Mutational analysis of primary central nervous system lymphoma.

Authors:  Aurélie Bruno; Blandine Boisselier; Karim Labreche; Yannick Marie; Marc Polivka; Anne Jouvet; Clovis Adam; Dominique Figarella-Branger; Catherine Miquel; Sandrine Eimer; Caroline Houillier; Carole Soussain; Karima Mokhtari; Romain Daveau; Khê Hoang-Xuan
Journal:  Oncotarget       Date:  2014-07-15
View more
  139 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

2.  Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.

Authors:  Xiaolong Alan Zhou; Abner Louissaint; Alexander Wenzel; Jingyi Yang; Maria Estela Martinez-Escala; Andrea P Moy; Elizabeth A Morgan; Christian N Paxton; Bo Hong; Erica F Andersen; Joan Guitart; Amir Behdad; Lorenzo Cerroni; David M Weinstock; Jaehyuk Choi
Journal:  J Invest Dermatol       Date:  2018-05-30       Impact factor: 8.551

3.  High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Sehui Kim; Soo Jeong Nam; Changhee Park; Dohee Kwon; Jeemin Yim; Seung Geun Song; Chan-Young Ock; Young A Kim; Sung Hye Park; Tae Min Kim; Yoon Kyung Jeon
Journal:  Oncoimmunology       Date:  2019-06-10       Impact factor: 8.110

Review 4.  An Update on the Use of Immunotherapy in the Treatment of Lymphoma.

Authors:  Thomas U Marron; Matko Kalac; Joshua Brody
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 5.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 6.  Targeting the programmed death-1 pathway in lymphoid neoplasms.

Authors:  Chi Young Ok; Ken H Young
Journal:  Cancer Treat Rev       Date:  2017-02-11       Impact factor: 12.111

Review 7.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

8.  The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs.

Authors:  Leandro Venturutti; Ari M Melnick
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

9.  Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.

Authors:  Michelle J Lee; Jean L Koff; Jeffrey M Switchenko; C Ileen Jhaney; R Andrew Harkins; Sharvil P Patel; Sandeep S Dave; Christopher R Flowers
Journal:  Cancer       Date:  2020-05-29       Impact factor: 6.860

10.  Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Authors:  Aaron M Goodman; David Piccioni; Shumei Kato; Amélie Boichard; Huan-You Wang; Garrett Frampton; Scott M Lippman; Caitlin Connelly; David Fabrizio; Vincent Miller; Jason K Sicklick; Razelle Kurzrock
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.